Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Elanco Animal Health (ELAN) and R1 RCM (RCM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE – Research Report), Elanco Animal Health (ELAN – Research Report) and R1 RCM (RCM – Research Report) with bullish sentiments.

Fate Therapeutics (FATE)

Fate Therapeutics received a Buy rating and a $10.00 price target from Barclays analyst Peter Lawson yesterday. The company’s shares closed last Monday at $6.95, close to its 52-week high of $7.74.

According to TipRanks.com, Lawson is a 5-star analyst with an average return of 11.3% and a 48.3% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Springworks Therapeutics, and Iovance Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fate Therapeutics with a $9.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Elanco Animal Health (ELAN)

Barclays analyst Balaji Prasad reiterated a Buy rating on Elanco Animal Health yesterday and set a price target of $19.00. The company’s shares closed last Monday at $16.26, close to its 52-week high of $16.88.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 4.1% and a 48.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Pacira Pharmaceuticals, and Amneal Pharmaceuticals.

Elanco Animal Health has an analyst consensus of Moderate Buy, with a price target consensus of $17.21.

R1 RCM (RCM)

In a report released yesterday, Stephanie Davis from Barclays maintained a Buy rating on R1 RCM, with a price target of $14.00. The company’s shares closed last Monday at $13.89.

According to TipRanks.com, Davis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.7% and a 43.2% success rate. Davis covers the Healthcare sector, focusing on stocks such as Computer Programs and Systems, Walgreens Boots Alliance, and Lifestance Health Group.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for R1 RCM with a $15.85 average price target, implying a 12.8% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on FATE:

• Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
• Fate Therapeutics Inc (FATE) Q4 Earnings Cheat Sheet
• Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
• Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• Biotech Alert: Searches spiking for these stocks today